首站-论文投稿智能助手
典型文献
Liposome based drug delivery as a potential treatment option for Alzheimer's disease
文献摘要:
Alzheimer's disease is a neurodegenerative condition leading to atrophy of the brain and robbing nearly 5.8 million individuals in the United States age 65 and older of their cognitive functions.Alzheimer's disease is associated with dementia and a progressive decline in memory,thinking,and social skills,eventually leading to a point that the individual can no longer perform daily activities independently.Currently available drugs on the market temporarily alleviate the symptoms,however,they are not successful in slowing down the progression of Alzheimer's disease.Treatment and cures have been constricted due to the difficulty of drug delivery to the blood-brain barrier.Several studies have led to identification of vesicles to transport the necessary drugs through the blood-brain barrier that would typically not achieve the targeted area through systemic delivered medications.Recently,liposomes have emerged as a viable drug delivery agent to transport drugs that are not able to cross the blood-brain barrier.Liposomes are being used as a component of nanoparticle drug delivery;due to their biocompatible nature;and possessing the capability to carry both lipophilic and hydrophilic therapeutic agents across the blood brain barrier into the brain cells.Studies indicate the importance of liposomal based drug delivery in treatment of neurodegenerative disorders.The idea is to encapsulate the drugs inside the properly engineered liposome to generate a response of treatment.Liposomes are engineered to target specific diseased moieties and also several surface modifications of liposomes are under research to create a clinical path to the management of Alzheimer's disease.This review deals with Alzheimer's disease and emphasize on challenges associated with drug delivery to the brain,and how liposomal drug delivery can play an important role as a drug delivery method for the treatment of Alzheimer's disease.This review also sheds some light on variation of liposomes.Additionally,it emphasizes on the liposomal formulations which are currently researched or used for treatment of Alzheimer's disease and also discusses the future prospect of liposomal based drug delivery in Alzheimer's disease.
文献关键词:
作者姓名:
Carely Hernandez;Surabhi Shukla
作者机构:
Department of Pharmaceutical Sciences,College of Pharmacy,Larkin University,Miami,FL,USA
引用格式:
[1]Carely Hernandez;Surabhi Shukla-.Liposome based drug delivery as a potential treatment option for Alzheimer's disease)[J].中国神经再生研究(英文版),2022(06):1190-1198
A类:
Liposome,robbing,cures
B类:
delivery,potential,treatment,option,Alzheimer,neurodegenerative,condition,leading,atrophy,brain,nearly,million,individuals,United,States,older,their,cognitive,functions,associated,dementia,progressive,decline,memory,thinking,social,skills,eventually,point,that,can,longer,perform,daily,activities,independently,Currently,available,drugs,market,temporarily,alleviate,symptoms,however,they,not,successful,slowing,down,progression,Treatment,have,been,constricted,due,difficulty,blood,barrier,Several,studies,led,identification,vesicles,transport,necessary,through,would,typically,achieve,targeted,area,systemic,delivered,medications,Recently,liposomes,emerged,viable,Liposomes,being,used,component,nanoparticle,biocompatible,nature,possessing,capability,carry,both,lipophilic,hydrophilic,therapeutic,agents,across,into,cells,Studies,indicate,importance,liposomal,disorders,idea,encapsulate,inside,properly,engineered,generate,response,specific,diseased,moieties,also,several,surface,modifications,under,create,clinical,path,management,This,review,deals,challenges,play,important,role,method,sheds,light,variation,Additionally,emphasizes,formulations,which,currently,researched,discusses,future,prospect
AB值:
0.50596
相似文献
Dementia in military and veteran populations: a review of risk factors—traumatic brain injury, post?traumatic stress disorder, deployment, and sleep
Zara Raza;Syeda F.Hussain;Suzanne Ftouni;Gershon Spitz;Nick Caplin;Russell G.Foster;Renata S.M.Gomes-Research and Innovation,Blind Veterans UK,12?14 Harcourt Street,London W1H 4HD,UK;BRAVO VICTOR,Research,12?14 Harcourt Street,London W1H 4HD,UK;Circadian Therapeutics,Oxford OX11BY,UK;School of Psychological Sciences,Monash University,18 Innovation Walk,Clayton Campus,Wellington Road,Melbourne,VIC 3800,Australia;Sleep&Circadian Neuroscience Institute (SCNi),Nuffield Department of Clinical Neurosciences,Sir William Dunn School of Pathology,Oxford Molecular Pathology Institute,University of Oxford,South Parks Road,Oxford OX13RF,UK;Northern Hub for Veterans and Military Families Research,Department of Nursing,Midwifery and Health,Faculty of Health and Life Sciences,Northumbria University,Newcastle NE77XA,UK
A randomized controlled trial to evaluate efficacy and safety of early conversion to a low-dose calcineurin inhibitor combined with sirolimus in renal transplant patients
Zheng Xiang;Zhang Weijie;Zhou Hua;Cao Ronghua;Shou Zhangfei;Zhang Shuwei;Cheng Ying;Chen Xuchun;Ding Chenguang;Tang Zuofu;Li Ning;Shi Shaohua;Zhou Qiang;Chen Qiuyuan;Chen Gang;Chen Zheng;Zhou Peijun;Hu Xiaopeng;Zhang Xiaodong;Na Ning;Wang Wei-Department of Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing 100020, China;Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430032, China;Kidney Transplantation Dialysis Center, The Second People’s Hospital of Shanxi Province, Taiyuan, Shanxi 030012, China;Department of Organ Transplantation, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong 510120, China;Department of Nephrology, Shulan (Hangzhou) Hospital, Hangzhou, Zhejiang 310000, China;Department of Urology, Ningbo Yinzhou Number. 2 Hospital, Ningbo, Zhejiang 315000, China;Department of Organ Transplantation, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China;Institute of Kidney Transplantation, The First Affiliated Hospital, Medical College of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China;Department of Kidney, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510630, China;Department of Kidney, Southwest Hospital, The First Hospital Affiliated to The Third Military Medical University (Army Medical University), Chongqing 400000, China;Organ Transplant Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, China;Kidney Transplantation Center, Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200000, China
Structural basis of the activation of metabotropic glutamate receptor 3
Wei Fang;Fan Yang;Chanjuan Xu;Shenglong Ling;Li Lin;Yingxin Zhou;Wenjing Sun;Xiaomei Wang;Peng Liu;Philippe Rondard;Pan Shi;Jean-Philippe Pin;Changlin Tian;Jianfeng Liu-The First Affiliated Hospital of USTC,School of Life Sciences,Division of Life Sciences and Medicine,Joint Center for Biological Analytical Chemistry,Anhui Engineering Laboratory of Peptide Drug,Anhui Laboratory of Advanced Photonic Science and Technology,University of Science and Technology of China,Hefei,Anhui,China;Key Laboratory of Molecular Biophysics of MOE,International Research Center for Sensory Biology and Technology of MOST,College of Life Science and Technology,Huazhong University of Science and Technology(HUST),Wuhan,Hubei,China;Bioland Laboratory,Guangzhou Regenerative Medicine and Health Guangdong Laboratory,Guangzhou,Guangdong,China;Institut de Génomique Fonctionnelle(IGF),Université de Montpellier,CNRS,INSERM,Montpellier,France
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。